195 related articles for article (PubMed ID: 26823210)
21. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
[TBL] [Abstract][Full Text] [Related]
23. Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler.
Zetterström O; Dahl R; Lindqvist A; Olsson P
Respir Med; 2008 Oct; 102(10):1406-11. PubMed ID: 18640826
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
[TBL] [Abstract][Full Text] [Related]
25. Knemometry Assessment of Short-term Growth in Children With Asthma Receiving Fluticasone Furoate for 2 Weeks: A Randomized, Placebo-controlled, Crossover Trial.
Wolthers OD; Stone S; Bareille P; Tomkins S; Khindri S
Clin Ther; 2017 Jun; 39(6):1191-1199. PubMed ID: 28545804
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L; Bateman ED
Thorax; 2013 Jun; 68(6):513-20. PubMed ID: 23440247
[TBL] [Abstract][Full Text] [Related]
27. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial.
Busse WW; Bateman ED; O'Byrne PM; Lötvall J; Woodcock A; Medley H; Forth R; Jacques L
Allergy; 2014 Nov; 69(11):1522-30. PubMed ID: 25040613
[TBL] [Abstract][Full Text] [Related]
28. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
29. Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma.
Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
J Pediatr; 2016 Nov; 178():246-253.e2. PubMed ID: 27622699
[TBL] [Abstract][Full Text] [Related]
30. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT; Deans A; Mehta R; Sousa AR
Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
[TBL] [Abstract][Full Text] [Related]
31. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
O'Byrne PM; Bleecker ER; Bateman ED; Busse WW; Woodcock A; Forth R; Toler WT; Jacques L; Lötvall J
Eur Respir J; 2014 Mar; 43(3):773-82. PubMed ID: 24136330
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
Sterling R; Lim J; Frith L; Snowise NG; Jacques L; Haumann B
Respir Med; 2012 Aug; 106(8):1110-5. PubMed ID: 22520084
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
Corren J; Mansfield LE; Pertseva T; Blahzko V; Kaiser K
Respir Med; 2013 Feb; 107(2):180-95. PubMed ID: 23273405
[TBL] [Abstract][Full Text] [Related]
34. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
Allen A; Schenkenberger I; Trivedi R; Cole J; Hicks W; Gul N; Jacques L
Clin Respir J; 2013 Oct; 7(4):397-406. PubMed ID: 23578031
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
[TBL] [Abstract][Full Text] [Related]
38. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids.
Kerwin E; Pascoe S; Bailes Z; Nathan R; Bernstein D; Dahl R; von Maltzahn R; Robbins K; Fowler A; Lee L
Respir Res; 2020 Jun; 21(1):148. PubMed ID: 32532275
[TBL] [Abstract][Full Text] [Related]
39. Once-daily evening administration of mometasone furoate in asthma treatment initiation.
Bensch GW; Prenner B; Berkowitz R; Galant S; Ramsdell J; Lutsky B
Ann Allergy Asthma Immunol; 2006 Apr; 96(4):533-40. PubMed ID: 16680923
[TBL] [Abstract][Full Text] [Related]
40. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.
O'Byrne PM; Jacques L; Goldfrad C; Kwon N; Perrio M; Yates LJ; Busse WW
Respir Res; 2016 Nov; 17(1):157. PubMed ID: 27881132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
